BMS-986165 - BMS
BMS-986165: Data from P2 trial (NCT03934216) for moderate-to-severe ulcerative colitis in 2021 (Bristol-Myers Squibb) - Jun 27, 2020 - Investor Series Immunology and Cardiovascular: Data from P2 trial (NCT03599622) for moderate-to-severe Crohn's disease in 2022 or later 
P2 data Crohn's disease • Inflammatory Bowel Disease • Ulcerative Colitis
https://www.bms.com/investors/events-and-presentations.html
 
Jun 27, 2020
 
 
d3659a9a-0d9a-4d2b-9c1e-39fd2aff1d3c.jpg